Cost-effectiveness  ||| S:0 E:19 ||| NNP
and  ||| S:19 E:23 ||| CC
cost-utility  ||| S:23 E:36 ||| JJ
analysis  ||| S:36 E:45 ||| NN
of  ||| S:45 E:48 ||| IN
OTC  ||| S:48 E:52 ||| NNP
use  ||| S:52 E:56 ||| NN
of  ||| S:56 E:59 ||| IN
simvastatin  ||| S:59 E:71 ||| CD
10  ||| S:71 E:74 ||| CD
mg  ||| S:74 E:77 ||| NN
for  ||| S:77 E:81 ||| IN
the  ||| S:81 E:85 ||| DT
primary  ||| S:85 E:93 ||| JJ
prevention  ||| S:93 E:104 ||| NN
of  ||| S:104 E:107 ||| IN
myocardial  ||| S:107 E:118 ||| JJ
infarction  ||| S:118 E:129 ||| NN
in  ||| S:129 E:132 ||| IN
Iranian  ||| S:132 E:140 ||| JJ
men  ||| S:140 E:144 ||| NNS
Several  ||| S:144 E:152 ||| JJ
clinical  ||| S:152 E:161 ||| JJ
trials  ||| S:161 E:168 ||| NNS
and  ||| S:168 E:172 ||| CC
meta-analyses  ||| S:172 E:186 ||| NNS
have  ||| S:186 E:191 ||| VBP
shown  ||| S:191 E:197 ||| VBN
the  ||| S:197 E:201 ||| DT
advantageous  ||| S:201 E:214 ||| JJ
effects  ||| S:214 E:222 ||| NNS
of  ||| S:222 E:225 ||| IN
statins  ||| S:225 E:233 ||| NN
in  ||| S:233 E:236 ||| IN
populations  ||| S:236 E:248 ||| NNS
with  ||| S:248 E:253 ||| IN
different  ||| S:253 E:263 ||| JJ
levels  ||| S:263 E:270 ||| NNS
of  ||| S:270 E:273 ||| IN
cardiovascular  ||| S:273 E:288 ||| JJ
disease  ||| S:288 E:296 ||| NN
( ||| S:296 E:297 ||| -LRB-
CVD ||| S:297 E:300 ||| NNP
)  ||| S:300 E:302 ||| -RRB-
risk ||| S:302 E:306 ||| NN
.  ||| S:306 E:308 ||| .
Considering  ||| S:308 E:320 ||| VBG
the  ||| S:320 E:324 ||| DT
increasing  ||| S:324 E:335 ||| VBG
cardiovascular  ||| S:335 E:350 ||| JJ
risk  ||| S:350 E:355 ||| NN
among  ||| S:355 E:361 ||| IN
the  ||| S:361 E:365 ||| DT
Iranian  ||| S:365 E:373 ||| JJ
population ||| S:373 E:383 ||| NN
,  ||| S:383 E:385 ||| ,
the  ||| S:385 E:389 ||| DT
cost-effectiveness  ||| S:389 E:408 ||| JJ
of  ||| S:408 E:411 ||| IN
the  ||| S:411 E:415 ||| DT
use  ||| S:415 E:419 ||| NN
of  ||| S:419 E:422 ||| IN
simvastatin  ||| S:422 E:434 ||| CD
10  ||| S:434 E:437 ||| CD
mg ||| S:437 E:439 ||| NN
,  ||| S:439 E:441 ||| ,
as  ||| S:441 E:444 ||| IN
an  ||| S:444 E:447 ||| DT
Over-The-Counter  ||| S:447 E:464 ||| JJ
( ||| S:464 E:465 ||| -LRB-
OTC ||| S:465 E:468 ||| NNP
)  ||| S:468 E:470 ||| -RRB-
drug ||| S:470 E:474 ||| NN
,  ||| S:474 E:476 ||| ,
for  ||| S:476 E:480 ||| IN
the  ||| S:480 E:484 ||| DT
primary  ||| S:484 E:492 ||| JJ
prevention  ||| S:492 E:503 ||| NN
of  ||| S:503 E:506 ||| IN
myocardial  ||| S:506 E:517 ||| JJ
infarction  ||| S:517 E:528 ||| NNS
( ||| S:528 E:529 ||| -LRB-
MI ||| S:529 E:531 ||| NNP
)  ||| S:531 E:533 ||| -RRB-
was  ||| S:533 E:537 ||| VBD
evaluated  ||| S:537 E:547 ||| VBN
in  ||| S:547 E:550 ||| IN
this  ||| S:550 E:555 ||| DT
modeling  ||| S:555 E:564 ||| JJ
study ||| S:564 E:569 ||| NN
,  ||| S:569 E:571 ||| ,
from  ||| S:571 E:576 ||| IN
the  ||| S:576 E:580 ||| DT
payer ||| S:580 E:585 ||| NN
's  ||| S:585 E:588 ||| POS
perspective ||| S:588 E:599 ||| NN
.  ||| S:599 E:601 ||| .
The  ||| S:601 E:605 ||| DT
target  ||| S:605 E:612 ||| NN
population  ||| S:612 E:623 ||| NN
is  ||| S:623 E:626 ||| VBZ
a  ||| S:626 E:628 ||| DT
hypothetical  ||| S:628 E:641 ||| JJ
cohort  ||| S:641 E:648 ||| NN
of  ||| S:648 E:651 ||| IN
45-year  ||| S:651 E:659 ||| NNP
CVD  ||| S:659 E:663 ||| NNP
healthy  ||| S:663 E:671 ||| JJ
men  ||| S:671 E:675 ||| NNS
with  ||| S:675 E:680 ||| IN
an  ||| S:680 E:683 ||| DT
average  ||| S:683 E:691 ||| NN
( ||| S:691 E:692 ||| -LRB-
15 ||| S:692 E:694 ||| CD
% ||| S:694 E:695 ||| NN
)  ||| S:695 E:697 ||| -RRB-
10-year  ||| S:697 E:705 ||| JJ
CVD  ||| S:705 E:709 ||| NNP
risk ||| S:709 E:713 ||| NN
.  ||| S:713 E:715 ||| .
A  ||| S:715 E:717 ||| DT
semi-Markov  ||| S:717 E:729 ||| JJ
model  ||| S:729 E:735 ||| NN
with  ||| S:735 E:740 ||| IN
a  ||| S:740 E:742 ||| DT
life-long  ||| S:742 E:752 ||| JJ
time  ||| S:752 E:757 ||| NN
horizon  ||| S:757 E:765 ||| NN
was  ||| S:765 E:769 ||| VBD
developed  ||| S:769 E:779 ||| VBN
to  ||| S:779 E:782 ||| TO
evaluate  ||| S:782 E:791 ||| VB
the  ||| S:791 E:795 ||| DT
Cost-Utility-Analysis  ||| S:795 E:817 ||| JJ
( ||| S:817 E:818 ||| -LRB-
CUA ||| S:818 E:821 ||| NNP
)  ||| S:821 E:823 ||| -RRB-
and  ||| S:823 E:827 ||| CC
Cost-Effectiveness-Analysis  ||| S:827 E:855 ||| NNP
( ||| S:855 E:856 ||| -LRB-
CEA ||| S:856 E:859 ||| NNP
)  ||| S:859 E:861 ||| -RRB-
of  ||| S:861 E:864 ||| IN
the  ||| S:864 E:868 ||| DT
use  ||| S:868 E:872 ||| NN
of  ||| S:872 E:875 ||| IN
OTC  ||| S:875 E:879 ||| NNP
simvastatin  ||| S:879 E:891 ||| VBD
10  ||| S:891 E:894 ||| CD
mg  ||| S:894 E:897 ||| NNS
compared  ||| S:897 E:906 ||| VBN
to  ||| S:906 E:909 ||| TO
no-drug  ||| S:909 E:917 ||| JJ
therapy ||| S:917 E:924 ||| NN
.  ||| S:924 E:926 ||| .
Two  ||| S:926 E:930 ||| CD
measures  ||| S:930 E:939 ||| NNS
of  ||| S:939 E:942 ||| IN
benefits  ||| S:942 E:951 ||| NNS
were  ||| S:951 E:956 ||| VBD
used  ||| S:956 E:961 ||| VBN
in  ||| S:961 E:964 ||| IN
the  ||| S:964 E:968 ||| DT
model ||| S:968 E:973 ||| NN
;  ||| S:973 E:975 ||| :
Quality-Adjusted-Life-Years  ||| S:975 E:1003 ||| NNP
( ||| S:1003 E:1004 ||| -LRB-
QALYs ||| S:1004 E:1009 ||| NNP
)  ||| S:1009 E:1011 ||| -RRB-
for  ||| S:1011 E:1015 ||| IN
the  ||| S:1015 E:1019 ||| DT
CUA  ||| S:1019 E:1023 ||| NNP
and  ||| S:1023 E:1027 ||| CC
Life-Years-Gained  ||| S:1027 E:1045 ||| NNP
( ||| S:1045 E:1046 ||| -LRB-
LYG ||| S:1046 E:1049 ||| NNP
)  ||| S:1049 E:1051 ||| -RRB-
for  ||| S:1051 E:1055 ||| IN
the  ||| S:1055 E:1059 ||| DT
CEA ||| S:1059 E:1062 ||| NNP
.  ||| S:1062 E:1064 ||| .
To  ||| S:1064 E:1067 ||| TO
examine  ||| S:1067 E:1075 ||| VB
the  ||| S:1075 E:1079 ||| DT
robustness  ||| S:1079 E:1090 ||| NN
of  ||| S:1090 E:1093 ||| IN
the  ||| S:1093 E:1097 ||| DT
results ||| S:1097 E:1104 ||| NNS
,  ||| S:1104 E:1106 ||| ,
one-way  ||| S:1106 E:1114 ||| JJ
sensitivity  ||| S:1114 E:1126 ||| NN
analysis  ||| S:1126 E:1135 ||| NN
and  ||| S:1135 E:1139 ||| CC
probabilistic  ||| S:1139 E:1153 ||| JJ
sensitivity  ||| S:1153 E:1165 ||| NN
analysis  ||| S:1165 E:1174 ||| NN
were  ||| S:1174 E:1179 ||| VBD
applied  ||| S:1179 E:1187 ||| VBN
to  ||| S:1187 E:1190 ||| TO
the  ||| S:1190 E:1194 ||| DT
model ||| S:1194 E:1199 ||| NN
.  ||| S:1199 E:1201 ||| .
For  ||| S:1201 E:1205 ||| IN
the  ||| S:1205 E:1209 ||| DT
base-case  ||| S:1209 E:1219 ||| JJ
scenario  ||| S:1219 E:1228 ||| NN
with  ||| S:1228 E:1233 ||| IN
a  ||| S:1233 E:1235 ||| DT
discount  ||| S:1235 E:1244 ||| NN
rate  ||| S:1244 E:1249 ||| NN
of  ||| S:1249 E:1252 ||| IN
0 ||| S:1252 E:1253 ||| CD
%  ||| S:1253 E:1255 ||| NN
the  ||| S:1255 E:1259 ||| DT
estimated  ||| S:1259 E:1269 ||| JJ
ICERs  ||| S:1269 E:1275 ||| NN
were  ||| S:1275 E:1280 ||| VBD
1113  ||| S:1280 E:1285 ||| CD
USD ||| S:1285 E:1288 ||| NNP
/ ||| S:1288 E:1289 ||| NNP
QALY  ||| S:1289 E:1294 ||| NNP
and  ||| S:1294 E:1298 ||| CC
935USD ||| S:1298 E:1304 ||| FW
/ ||| S:1304 E:1305 ||| FW
LYG  ||| S:1305 E:1309 ||| FW
per  ||| S:1309 E:1313 ||| FW
patient  ||| S:1313 E:1321 ||| FW
( ||| S:1321 E:1322 ||| -LRB-
using  ||| S:1322 E:1328 ||| VBG
governmental  ||| S:1328 E:1341 ||| JJ
tariffs ||| S:1341 E:1348 ||| NNS
) ||| S:1348 E:1349 ||| -RRB-
.  ||| S:1349 E:1351 ||| .
No  ||| S:1351 E:1354 ||| DT
threshold  ||| S:1354 E:1364 ||| NN
has  ||| S:1364 E:1368 ||| VBZ
been  ||| S:1368 E:1373 ||| VBN
determined  ||| S:1373 E:1384 ||| VBN
in  ||| S:1384 E:1387 ||| IN
Iran  ||| S:1387 E:1392 ||| NNP
for  ||| S:1392 E:1396 ||| IN
the  ||| S:1396 E:1400 ||| DT
cost-effectiveness  ||| S:1400 E:1419 ||| JJ
of  ||| S:1419 E:1422 ||| IN
health-related  ||| S:1422 E:1437 ||| JJ
interventions ||| S:1437 E:1450 ||| NNS
.  ||| S:1450 E:1452 ||| .
However ||| S:1452 E:1459 ||| RB
,  ||| S:1459 E:1461 ||| ,
according  ||| S:1461 E:1471 ||| VBG
to  ||| S:1471 E:1474 ||| TO
the  ||| S:1474 E:1478 ||| DT
recommendation  ||| S:1478 E:1493 ||| NN
of  ||| S:1493 E:1496 ||| IN
WHO ||| S:1496 E:1499 ||| WP
,  ||| S:1499 E:1501 ||| ,
this  ||| S:1501 E:1506 ||| DT
intervention  ||| S:1506 E:1519 ||| NN
can  ||| S:1519 E:1523 ||| MD
be  ||| S:1523 E:1526 ||| VB
considered  ||| S:1526 E:1537 ||| VBN
highly  ||| S:1537 E:1544 ||| RB
cost-effective  ||| S:1544 E:1559 ||| JJ
as  ||| S:1559 E:1562 ||| IN
its  ||| S:1562 E:1566 ||| PRP$
ICER  ||| S:1566 E:1571 ||| NNP
is  ||| S:1571 E:1574 ||| VBZ
far  ||| S:1574 E:1578 ||| RB
less  ||| S:1578 E:1583 ||| JJR
than  ||| S:1583 E:1588 ||| IN
the  ||| S:1588 E:1592 ||| DT
reported  ||| S:1592 E:1601 ||| VBD
GDP  ||| S:1601 E:1605 ||| NNP
per  ||| S:1605 E:1609 ||| IN
capita  ||| S:1609 E:1616 ||| NN
for  ||| S:1616 E:1620 ||| IN
Iran  ||| S:1620 E:1625 ||| NNP
by  ||| S:1625 E:1628 ||| IN
World  ||| S:1628 E:1634 ||| NNP
bank  ||| S:1634 E:1639 ||| NN
in  ||| S:1639 E:1642 ||| IN
2013  ||| S:1642 E:1647 ||| CD
( ||| S:1647 E:1648 ||| -LRB-
$ ||| S:1648 E:1649 ||| $
4763 ||| S:1649 E:1653 ||| CD
) ||| S:1653 E:1654 ||| -RRB-
.  ||| S:1654 E:1656 ||| .
This  ||| S:1656 E:1661 ||| DT
modeling  ||| S:1661 E:1670 ||| JJ
study  ||| S:1670 E:1676 ||| NN
showed  ||| S:1676 E:1683 ||| VBD
that  ||| S:1683 E:1688 ||| IN
the  ||| S:1688 E:1692 ||| DT
use  ||| S:1692 E:1696 ||| NN
of  ||| S:1696 E:1699 ||| IN
an  ||| S:1699 E:1702 ||| DT
OTC  ||| S:1702 E:1706 ||| NNP
low  ||| S:1706 E:1710 ||| JJ
dose  ||| S:1710 E:1715 ||| NN
statin  ||| S:1715 E:1722 ||| NNS
( ||| S:1722 E:1723 ||| -LRB-
simvastatin  ||| S:1723 E:1735 ||| CD
10  ||| S:1735 E:1738 ||| CD
mg ||| S:1738 E:1740 ||| CD
)  ||| S:1740 E:1742 ||| -RRB-
for  ||| S:1742 E:1746 ||| IN
the  ||| S:1746 E:1750 ||| DT
primary  ||| S:1750 E:1758 ||| JJ
prevention  ||| S:1758 E:1769 ||| NN
of  ||| S:1769 E:1772 ||| IN
myocardial  ||| S:1772 E:1783 ||| JJ
infarction  ||| S:1783 E:1794 ||| NNS
( ||| S:1794 E:1795 ||| -LRB-
MI ||| S:1795 E:1797 ||| NNP
)  ||| S:1797 E:1799 ||| -RRB-
in  ||| S:1799 E:1802 ||| IN
45-year  ||| S:1802 E:1810 ||| CD
men  ||| S:1810 E:1814 ||| NNS
with  ||| S:1814 E:1819 ||| IN
a  ||| S:1819 E:1821 ||| DT
10-year  ||| S:1821 E:1829 ||| JJ
CVD  ||| S:1829 E:1833 ||| NNP
risk  ||| S:1833 E:1838 ||| NN
of  ||| S:1838 E:1841 ||| IN
15 ||| S:1841 E:1843 ||| CD
%  ||| S:1843 E:1845 ||| NN
could  ||| S:1845 E:1851 ||| MD
be  ||| S:1851 E:1854 ||| VB
considered  ||| S:1854 E:1865 ||| VBN
highly  ||| S:1865 E:1872 ||| RB
cost-effective  ||| S:1872 E:1887 ||| JJ
in  ||| S:1887 E:1890 ||| IN
Iran ||| S:1890 E:1894 ||| NNP
,  ||| S:1894 E:1896 ||| ,
as  ||| S:1896 E:1899 ||| IN
it  ||| S:1899 E:1902 ||| PRP
meets  ||| S:1902 E:1908 ||| VBZ
the  ||| S:1908 E:1912 ||| DT
WHO  ||| S:1912 E:1916 ||| WP
threshold  ||| S:1916 E:1926 ||| VBD
of  ||| S:1926 E:1929 ||| IN
the  ||| S:1929 E:1933 ||| DT
annual  ||| S:1933 E:1940 ||| JJ
GDP  ||| S:1940 E:1944 ||| NNP
per  ||| S:1944 E:1948 ||| FW
capita  ||| S:1948 E:1955 ||| FW
( ||| S:1955 E:1956 ||| -LRB-
$ ||| S:1956 E:1957 ||| $
4763 ||| S:1957 E:1961 ||| CD
) ||| S:1961 E:1962 ||| -RRB-
.  ||| S:1962 E:1964 ||| .
